Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication

dc.creatorAghamohammadi, Asghar
dc.creatorAbolhassani, Hassan
dc.creatorKutukculer, Necil
dc.creatorWassilak, Steve
dc.creatorPallansch, Mark
dc.creatorKluglein, Samantha
dc.creatorQuinn, Jessica
dc.creatorSutter, Roland
dc.creatorWang, Xiaochuan
dc.creatorSanal, Ozden
dc.creatorLatysheva, Tatiana
dc.creatorIkinciogullari, Aydan
dc.creatorBernatowska, Ewa
dc.creatorTuzankina, Irina
dc.creatorCosta Carvalho, Beatriz
dc.creatorFranco Restrepo, José Luis
dc.creatorSomech, Raz
dc.creatorKarakoc Aydiner, Elif
dc.creatorSingh, Surjit
dc.creatorBezrodnik, Liliana
dc.creatorEspinosa Rosales, Francisco
dc.creatorShcherbina, Anna
dc.creatorLung Lau, Yu
dc.creatorNonoyama, Shigeaki
dc.creatorModell, Fred
dc.creatorModell, Vicki
dc.creatorRidha Barbouche, Mohamed
dc.creatorMcKinlay, Mark
dc.date2019-07-23T16:56:45Z
dc.date2019-07-23T16:56:45Z
dc.date2017
dc.date.accessioned2023-08-28T20:53:17Z
dc.date.available2023-08-28T20:53:17Z
dc.identifierAghamohammadi A, Abolhassani H, Kutukculer N, Wassilak SG, Pallansch MA, Kluglein S, Quinn J, Sutter RW, Wang X, Sanal O, Latysheva T, Ikinciogullari A, Bernatowska E, Tuzankina IA, Costa-Carvalho BT, Franco JL, Somech R, Karakoc-Aydiner E, Singh S, Bezrodnik L, Espinosa-Rosales FJ, Shcherbina A, Lau YL, Nonoyama S, Modell F, Modell V; JMF Centers Network Investigators and Study Collaborators, Barbouche MR, McKinlay MA. Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication. Front Immunol. 2017 Jun 13;8:685.
dc.identifier1664-3224
dc.identifierhttp://hdl.handle.net/10495/11493
dc.identifier10.3389/fimmu.2017.00685
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8485655
dc.descriptionABSTARCT: Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame. Keywords: Poliovirus eradication, Immunodeficiency-associated vaccine-derived polioviruses, Oral poliovirus vaccine, Humoral immunodeficiency, Combined immunodeficiency, Primary immunodeficiency
dc.descriptionCOL0012426
dc.format9
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherFrontiers Research Foundation
dc.publisherInmunodeficiencias Primarias
dc.publisherSuiza
dc.relationFront Immunol
dc.rightsAtribución 2.5
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightshttp://creativecommons.org/licenses/by/2.5/co/
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.rightshttps://creativecommons.org/licenses/by/4.0/
dc.subjectPoliovirus derivados de vacuna
dc.subjectPoliovirus oral
dc.subjectVacuna antipoliomielítica oral
dc.subjectInmunodeficiencia humoral
dc.subjectInmunodeficiencia combinada
dc.subjectInmunodeficiencia primaria
dc.titlePatients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typehttp://purl.org/coar/resource_type/c_2df8fbb1
dc.typehttps://purl.org/redcol/resource_type/ART
dc.typeArtículo de investigación


Este ítem pertenece a la siguiente institución